Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Drug Does Not Improve Set of Cardiovascular Outcomes for Diastolic Heart Failure

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
NIH-supported study finds drug does appear to reduce hospitalizations for diastolic heart failure.

A drug that blocks the action of a key hormone did not significantly improve a set of cardiovascular outcomes for patients with diastolic heart failure, a condition in which the heart is stiffer than normal and has problems filling with blood, according to a study supported by the National Institutes of Health.

In terms of the study's primary aim, the results showed no difference in the overall combined endpoint treatments. The study did reduce the rate of heart failure hospitalizations, which was one of the endpoints, in the target population.

The drug, spironolactone, blocks the action of the hormone aldosterone, which is produced in excess in heart failure. The inexpensive generic drug currently is approved to treat patients with systolic heart failure, in which the heart muscle's pumping ability is reduced. There is no specific therapy for diastolic heart failure.

In the current trial, spironolactone did not improve the combined primary endpoints of cardiovascular death, hospitalization for heart failure, or aborted cardiac arrest. Aborted cardiac arrest is a stopped heart that is restarted by CPR or an implanted device.

NIH's National Heart, Lung, and Blood Institute (NHLBI) supported the work, which was published in the April 10 edition of the New England Journal of Medicine. The paper represents the primary results of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial.

Diastolic heart failure, also known as heart failure with preserved systolic function, is a common heart condition accounting for about half of all heart failure cases. The Centers for Disease Control and Prevention estimates that 5.7 million people in the United States have heart failure.

"Heart failure is the most common reason for hospital admissions in the Medicare population, and diastolic heart failure accounts for at least half of these admissions," said Dr. Bertram Pitt of the University of Michigan, Ann Arbor, TOPCAT's study chairman. "Given the high financial and societal costs of these hospitalizations, there is a critical need to find treatments to reduce them. However, no effective therapy for diastolic heart failure has been found to date."

The New England Research Institute and Brigham and Women's Hospital in Boston led the multi-center international research effort involving 3,445 participants, which makes it one of the largest diastolic heart failure trials to date. Researchers enrolled participants in 270 sites spread across the United States, Canada, Argentina, Brazil, the Republic of Georgia, and Russia. Trial participants were randomly placed on spironolactone or a matching placebo and followed for an average of three years.

For the spironolactone group, 319 participants experienced one of the primary outcomes versus 351 in the placebo group, a 9 percent reduction that did not reach statistical significance. For heart failure hospitalizations, 206 people in the spironolactone group were hospitalized versus 245 people in the placebo group, a statistically significant reduction of 16 percent.

"Although TOPCAT did not significantly decrease the combined endpoint or cardiovascular death, spironolactone is the first drug shown to reduce heart failure hospitalizations in this vulnerable population," said Brigham and Women's Hospital's Dr. Marc Pfeffer, the principal investigator.

Spironolactone showed no difference in other serious adverse events, such as dialysis, compared to placebo, although participants taking the drug had higher increased potassium levels than the control group. While use of spironolactone carries the risk of elevated blood potassium levels or reduced kidney function, these risks were low in TOPCAT and can be reduced in clinical practice with careful monitoring.

"This study is an important step in the effort to find effective treatments for diastolic heart failure patients," said Dr. Michael Lauer, director of the NHLBI's Division of Cardiovascular Sciences. "The study examined a broad cross-section of diastolic heart failure patients, and further data analysis may offer clues about sub groups that may particularly benefit from spironolactone treatment."

Initial analysis showed potentially different outcomes based on how a participant qualified for the study. Researchers used two methods to determine which patients with heart failure were eligible to enroll in the study. One method required looked for elevated levels of the hormone BNP, which is associated with more severe heart failure. The other method required looked at a person's history of heart failure hospitalization within the last year.

The study showed that participants enrolled via elevated BNP measurements who received spironolactone fared better in the composite of main outcomes than the BNP group enrolled in the placebo arm. Of the patients enrolled via the BNP criteria, there were 78 patients with events in the spironolactone arm and 116 patients with events in placebo group.

Further analysis showed significant geographic variation in event rates. For patients enrolled in Russia and the Republic of Georgia, 78 patients (10 percent) in the spironolactone arm and 71 patients (8 percent) in the placebo arm reached the composite primary endpoints. For patients in North and South America, 242 patients (27 percent) in the spironolactone arm and 280 patients (4 percent) in the placebo arm reached the composite primary endpoints.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Tuesday, November 24, 2015
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Friday, November 13, 2015
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.
Tuesday, November 10, 2015
NIH Researchers Link Single Gene Variation to Obesity
Variation in the BDNF gene may affect brain’s regulation of appetite, study suggests.
Saturday, October 31, 2015
Researchers Identify Potential Alternative to CRISPR-Cas Genome Editing Tools
New Cas enzymes shed light on evolution of CRISPR-Cas systems.
Saturday, October 31, 2015
Potential Alternative to CRISPR-Cas Genome Editing Tools
New Cas enzymes shed light on evolution of CRISPR-Cas systems.
Friday, October 23, 2015
Charting Genetic Variation Across the Globe
An international team of scientists has created the world’s largest catalog of human genetic differences in populations around the globe.
Tuesday, October 20, 2015
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Tuesday, October 20, 2015
Nuclear Transport Problems Linked to ALS and FTD
NIH-supported studies point to potential new target for treating neurodegenerative diseases.
Monday, October 19, 2015
Scientists Develop Genetic Blueprint of Inner Ear Cell Development
Two studies in mice use new technique to provide insight into cell development critical for hearing, balance.
Saturday, October 17, 2015
$21M Invested in Research Hubs in Developing Countries
The National Institutes of Health and other U.S. and Canadian partners are investing $20.9 million dollars over five years to establish seven regional research and training centers in low- and middle-income countries (LMICs).
Friday, October 09, 2015
NIH Breast Cancer Research to Focus On Prevention
A new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention, is being launched at the National Institutes of Health.
Friday, October 09, 2015
NIH Grantees Win 2015 Nobel Prize in Chemistry
The 2015 Nobel Prize in chemistry has been awarded to NIH grantees Paul Modrich, Ph.D., of the Howard Hughes Medical Institute and the Duke University School of Medicine, Durham, N.C.; and Aziz Sancar, M.D., Ph.D., of the University of North Carolina, Chapel Hill, N.C.,.
Thursday, October 08, 2015
NIH Announces High-Risk, High-Reward Research Awardees
NIH to fund 78 awards to support highly innovative biomedical research.
Wednesday, October 07, 2015
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Tuesday, October 06, 2015
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Biologists Induce Flatworms to Grow Heads and Brains of Other Species
Findings shed light on role of a new kind of epigenetic signaling in evolution, could yield clues for understanding birth defects and regeneration.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos